03 September 2019
Dechra Veterinary Products has unveiled another solution for sedation and premedication with the addition of Nerfasin® vet to its equine range.
Nerfasin vet, which contains the short acting alpha-2 agonist xylazine, is licensed for both sedation and premedication prior to general anaesthesia. It is available in two concentrations for convenience and flexibility - a 20 mg/ml (2%) solution and a 100 mg/ml (10%) solution allowing more convenient equine dosing.
Nerfasin vet, which is administered intravenously to equines, is on sale in 25 ml vials.
Dechra Brand Manager Emma Jennings said: “We are delighted to add Nerfasin to our extensive range of anaesthesia and analgesia for equine vets. It can be used in cases requiring anything from mild to deep sedation.
“Used in conjunction with Dechra’s Equine Anaesthesia App, it will allow vets to better tailor their protocols in line with a patient’s specific needs. The app is easy to use and navigate and aims to raise standards of anaesthesia analgesia in equine practice.”
For more information visit: www.dechra.co.uk/products/equine
Nerfasin® vet added to Dechra stable